{"id":83843,"date":"2026-05-08T15:44:44","date_gmt":"2026-05-08T10:14:44","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=83843"},"modified":"2026-05-08T15:44:47","modified_gmt":"2026-05-08T10:14:47","slug":"lupin-q4-pat-1460-crore","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/lupin-q4-pat-1460-crore\/","title":{"rendered":"Lupin Q4 PAT Surges 89 Percent to Rs 1460 Crore Revenue Up 33 Percent"},"content":{"rendered":"<div class=\"meta-block\"><\/div>\n<p><a href=\"https:\/\/univest.in\/user\/stocks\/lupin\/lupin-ltd-share-price-today\">Lupin<\/a> Q4 results for FY26 announced on 7 May 2026 delivered an outstanding performance with consolidated net income rising 89% year on year to Rs 1,460.4 crore. The Lupin Q4 revenue from operations grew 33% to Rs 7,391.9 crore, driven by exceptional North America generics performance with sales surging 55% year on year to Rs 3,514.5 crore. The Lupin Q4 EBITDA expanded 68% to Rs 2,171.1 crore reflecting strong operating leverage.<\/p>\n<p>Investors tracking Lupin Q4 results FY26 will note that North America contributed Rs 3,514.5 crore in revenue, followed by India at Rs 1,908.2 crore growing 12% year on year. The Lupin Q4 highlights include the successful US launch of Dapagliflozin tablets, the generic of Farxiga, and a tentative approval for Sugammadex injection, the generic of Bridion, representing significant commercial opportunities.<\/p>\n<p><a href=\"https:\/\/univest.in\/user\/log-in\"><strong>Get Free Stock Recommendations on Univest<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/lupin-q4-pat-1460-crore\/#Lupin_Q4_FY26_Results_at_a_Glance\" title=\"Lupin Q4 FY26 Results at a Glance\">Lupin Q4 FY26 Results at a Glance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/lupin-q4-pat-1460-crore\/#Key_Highlights_from_Lupin_Q4_FY26\" title=\"Key Highlights from Lupin Q4 FY26\">Key Highlights from Lupin Q4 FY26<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/lupin-q4-pat-1460-crore\/#North_America_Surge_Drives_Revenue_Outperformance\" title=\"North America Surge Drives Revenue Outperformance\">North America Surge Drives Revenue Outperformance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/lupin-q4-pat-1460-crore\/#India_Business_Steady_at_12_Percent_Growth\" title=\"India Business Steady at 12 Percent Growth\">India Business Steady at 12 Percent Growth<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/lupin-q4-pat-1460-crore\/#Complex_Generics_Pipeline_and_New_Approvals\" title=\"Complex Generics Pipeline and New Approvals\">Complex Generics Pipeline and New Approvals<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/lupin-q4-pat-1460-crore\/#Risks_to_Monitor\" title=\"Risks to Monitor\">Risks to Monitor<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/lupin-q4-pat-1460-crore\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/lupin-q4-pat-1460-crore\/#Frequently_Asked_Questions\" title=\"Frequently Asked Questions\">Frequently Asked Questions<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/lupin-q4-pat-1460-crore\/#What_was_the_Lupin_Q4_FY26_PAT\" title=\"What was the Lupin Q4 FY26 PAT?\">What was the Lupin Q4 FY26 PAT?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/lupin-q4-pat-1460-crore\/#What_is_the_Lupin_Q4_FY26_revenue\" title=\"What is the Lupin Q4 FY26 revenue?\">What is the Lupin Q4 FY26 revenue?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/lupin-q4-pat-1460-crore\/#What_drove_Lupin_Q4_North_America_growth\" title=\"What drove Lupin Q4 North America growth?\">What drove Lupin Q4 North America growth?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/lupin-q4-pat-1460-crore\/#What_new_products_did_Lupin_receive_approval_for_in_Q4\" title=\"What new products did Lupin receive approval for in Q4?\">What new products did Lupin receive approval for in Q4?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/lupin-q4-pat-1460-crore\/#What_is_Lupin_Q4_FY27_outlook\" title=\"What is Lupin Q4 FY27 outlook?\">What is Lupin Q4 FY27 outlook?<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/lupin-q4-pat-1460-crore\/#Recent_Article\" title=\"Recent Article\">Recent Article<\/a><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Lupin_Q4_FY26_Results_at_a_Glance\"><\/span><strong>Lupin Q4 FY26 Results at a Glance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table>\n<tbody>\n<tr>\n<th>Metric<\/th>\n<th>Q4 FY26 \/ FY26<\/th>\n<th>Change<\/th>\n<\/tr>\n<tr>\n<td>Q4 Revenue<\/td>\n<td>Rs 7,392 crore<\/td>\n<td>+33% YoY<\/td>\n<\/tr>\n<tr>\n<td>Q4 Consolidated PAT<\/td>\n<td>Rs 1,460.4 crore<\/td>\n<td>+89% YoY<\/td>\n<\/tr>\n<tr>\n<td>Q4 EBITDA<\/td>\n<td>Rs 2,171.1 crore<\/td>\n<td>+68% YoY<\/td>\n<\/tr>\n<tr>\n<td>North America Revenue<\/td>\n<td>Rs 3,514.5 crore<\/td>\n<td>+55% YoY<\/td>\n<\/tr>\n<tr>\n<td>India Revenue<\/td>\n<td>Rs 1,908.2 crore<\/td>\n<td>+12% YoY<\/td>\n<\/tr>\n<tr>\n<td>EMEA Revenue<\/td>\n<td>Growing<\/td>\n<td>+19% YoY<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Track live financials and analyst ratings on the <a href=\"https:\/\/univest.in\/screeners\"><strong>Univest Screener<\/strong><\/a>.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Highlights_from_Lupin_Q4_FY26\"><\/span><strong>Key Highlights from Lupin Q4 FY26<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"North_America_Surge_Drives_Revenue_Outperformance\"><\/span><strong>North America Surge Drives Revenue Outperformance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The Lupin Q4 North America revenue surged 55% year on year to Rs 3,514.5 crore, driven by complex generics launches, volume share gains in existing products, and the commercial success of newly approved molecules. The Lupin Q4 North America performance was supported by the successful launch of generic Dapagliflozin tablets, a high-value diabetes medication with significant addressable market in the US generics space.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"India_Business_Steady_at_12_Percent_Growth\"><\/span><strong>India Business Steady at 12 Percent Growth<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The Lupin Q4 India business grew 12% year on year to Rs 1,908.2 crore, with cardiovascular, respiratory, diabetology, and GI therapeutic segments contributing broad-based growth. The Lupin Q4 India performance reflects the company&#8217;s strong field force and brand equity in key doctor segments, and aligns with the broader branded generics market growth in India.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Complex_Generics_Pipeline_and_New_Approvals\"><\/span><strong>Complex Generics Pipeline and New Approvals<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The Lupin Q4 results were supported by a robust pipeline of complex generics and specialty products receiving US FDA approvals. The Lupin Q4 period included a tentative approval for Sugammadex injection, the generic of Bridion used for anaesthesia reversal, which represents a significant commercial opportunity once the exclusivity period clears. The Lupin Q4 pipeline of respiratory, ophthalmology, and dermatology complex generics provides multi-year revenue visibility.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Risks_to_Monitor\"><\/span><strong>Risks to Monitor<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li><strong>US price erosion:<\/strong> Generic drug price erosion in North America can compress Lupin Q4 realisations on its existing product portfolio, even as volumes grow.<\/li>\n<li><strong>Regulatory risk:<\/strong> US FDA warning letters or import alerts at manufacturing sites could disrupt Lupin Q4 product approvals and shipments.<\/li>\n<li><strong>Competition in gDapagliflozin:<\/strong> Increasing competition from other generic entrants in Dapagliflozin could reduce market share and pricing over time.<\/li>\n<li><strong>India branded generics competition:<\/strong> Competition from MNCs and domestic pharma peers in key therapeutic segments creates pricing pressure on Lupin Q4 India business.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The Lupin Q4 results FY26 confirm a breakout year with PAT up 89% to Rs 1,460.4 crore and revenue up 33% to Rs 7,391.9 crore, powered by North America generics outperformance. The Lupin Q4 results validate the company&#8217;s multi-year R and D investment in complex generics that are now generating commercial returns.<\/p>\n<p>For FY27, the most important variable for Lupin Q4 investors is whether North America revenue growth sustains above 20% through new complex generics launches, and whether the India business can re-accelerate from 12% to 15% growth through new product launches and therapy segment expansion.<\/p>\n<p>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\"><strong>Univest iOS App<\/strong><\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\"><strong>Univest Android App<\/strong><\/a> for live Q4 results tracking and expert research.<\/p>\n<p><strong>Disclaimer:<\/strong> This article is for educational and informational purposes only and does not constitute investment advice. Univest analysts are SEBI-registered research analysts (SEBI RA: INH000012449). Investments in the securities market are subject to market risk. Consult a SEBI-registered financial advisor before making any investment decisions.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions\"><\/span><strong>Frequently Asked Questions<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_was_the_Lupin_Q4_FY26_PAT\"><\/span><strong>What was the Lupin Q4 FY26 PAT?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Lupin Q4 FY26 consolidated net income was Rs 1,460.4 crore, up 89% year on year, driven by North America generics surge of 55% and operating leverage with EBITDA growing 68% to Rs 2,171 crore.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_Lupin_Q4_FY26_revenue\"><\/span><strong>What is the Lupin Q4 FY26 revenue?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Lupin Q4 FY26 consolidated revenue from operations was Rs 7,391.9 crore, up 33% year on year. North America contributed Rs 3,514.5 crore up 55% and India contributed Rs 1,908.2 crore up 12%.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_drove_Lupin_Q4_North_America_growth\"><\/span><strong>What drove Lupin Q4 North America growth?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Lupin Q4 North America revenue surged 55% driven by the launch of generic Dapagliflozin tablets, volume share gains in existing generics, and the scale-up of complex generics in respiratory, dermatology, and other therapeutic areas.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_new_products_did_Lupin_receive_approval_for_in_Q4\"><\/span><strong>What new products did Lupin receive approval for in Q4?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Lupin Q4 received a tentative approval for Sugammadex injection, the generic of Bridion for anaesthesia reversal. The company also launched generic Dapagliflozin during the quarter, and secured US FDA approval for generic Liraglutide.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_Lupin_Q4_FY27_outlook\"><\/span><strong>What is Lupin Q4 FY27 outlook?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Lupin Q4 FY27 depends on sustaining North America complex generics momentum, India business re-acceleration, and successful commercialisation of the tentatively approved Sugammadex injection once exclusivity clears.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Recent_Article\"><\/span><strong>Recent Article<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p class=\"text-xl font-bold font-Inter mb-4\"><a href=\"https:\/\/univest.in\/blogs\/why-is-liberty-shoes-share-price-falling\">Why Is Liberty Shoes Share Price Falling: Key Reasons and Investor Analysis 2026<\/a><\/p>\n<p class=\"text-xl font-bold font-Inter mb-4\"><a href=\"https:\/\/univest.in\/blogs\/why-is-shemaroo-entertainment-share-price-falling\">Why Is Shemaroo Entertainment Share Price Falling: Key Reasons and Investor Analysis 2026<\/a><\/p>\n<p class=\"text-xl font-bold font-Inter mb-4\"><a href=\"https:\/\/univest.in\/blogs\/why-is-orchid-pharma-share-price-falling\">Why Is Orchid Pharma Share Price Falling: Key Reasons and Investor Analysis 2026<\/a><\/p>\n<p class=\"text-xl font-bold font-Inter mb-4\"><a href=\"https:\/\/univest.in\/blogs\/why-is-bajaj-holdings-and-investment-share-price-falling\">Why Is Bajaj Holdings and Investment Share Price Falling: Key Reasons and Investor Analysis 2026<\/a><\/p>\n<p class=\"text-xl font-bold font-Inter mb-4\"><a href=\"https:\/\/univest.in\/blogs\/why-is-prism-johnson-share-price-falling\">Why Is Prism Johnson Share Price Falling: Key Reasons and Investor Analysis 2026<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Lupin Q4 FY26 PAT Rs 1,460.4 crore up 89% YoY. Revenue Rs 7,392 crore up 33%. North America up 55% on gDapagliflozin launch. EBITDA Rs 2,171 crore up 68%. India up 12%.<\/p>\n","protected":false},"author":28,"featured_media":83978,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[3802,3858,3983],"class_list":["post-83843","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-news","tag-q4-results","tag-q4-results-2026"],"metadata":{"rank_math_internal_links_processed":["1"],"_edit_lock":["1778235291:28"],"_last_editor_used_jetpack":["block-editor"],"rank_math_primary_category":["842"],"rank_math_seo_score":["73"],"rank_math_title":["Lupin Q4 FY26 Results PAT Rs 1460 Cr Up 89 Percent Revenue Rs 7392 Crore"],"rank_math_description":["Lupin Q4 FY26 consolidated PAT surged 89% YoY to Rs 1,460.4 crore. Revenue rose 33% to Rs 7,391.9 crore. North America sales up 55%. EBITDA Rs 2,171 crore up 68%."],"rank_math_focus_keyword":["Lupin Q4"],"rank_math_robots":["a:2:{i:0;s:8:\"nofollow\";i:1;s:7:\"noindex\";}"],"_thumbnail_id":["83978"],"_edit_last":["28"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["10732"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/05\/08154415\/Lupin-Q4-Results.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/83843","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/28"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=83843"}],"version-history":[{"count":2,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/83843\/revisions"}],"predecessor-version":[{"id":83979,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/83843\/revisions\/83979"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/83978"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=83843"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=83843"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=83843"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}